| 12.95 -0.43 (-3.21%) | 09-09 11:15 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 17.9  |
1-year : | 20.73 |
| Resists | First : | 15.32 |
Second : | 17.75 |
| Pivot price | 14.28 |
|||
| Supports | First : | 11.4 | Second : | 9.49 |
| MAs | MA(5) : | 13.65 |
MA(20) : | 14.32 |
| MA(100) : | 14.22  |
MA(250) : | 20.9 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 16.4 |
D(3) : | 24.4 |
| RSI | RSI(14): 37.5 |
|||
| 52-week | High : | 35.58 | Low : | 9.92 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ QDEL ] has closed above bottom band by 0.9%. Bollinger Bands are 45.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 14.03 - 14.1 | 14.1 - 14.15 |
| Low: | 12.99 - 13.08 | 13.08 - 13.15 |
| Close: | 13.25 - 13.39 | 13.39 - 13.5 |
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
Sat, 05 Sep 2026
QuidelOrtho Appoints Micah Young as Chief Financial Officer - Eastern Progress
Tue, 18 Aug 2026
QuidelOrtho Corp (QDEL) exec’s RSUs vest as shares withheld for tax - Stock Titan
Mon, 10 Aug 2026
QuidelOrtho Corporation (QDEL) Stock Positioned for Reweighting Towards Peers Amid Deleveraging - Yahoo Finance
Thu, 06 Aug 2026
QuidelOrtho (NASDAQ:QDEL) Surprises With Q2 CY2026 Sales But Stock Drops 21.6% - StockStory
Thu, 06 Aug 2026
QuidelOrtho Reports Second Quarter 2026 Financial Results - PR Newswire
Fri, 24 Jul 2026
QuidelOrtho Results Will Arrive After Market Close Aug. 6 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Specialties
|
|
| Shares Out | 69 (M) |
| Shares Float | 61 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 124.6 (%) |
| Shares Short | 14,960 (K) |
| Shares Short P.Month | 11,800 (K) |
| EPS | -15.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 25.98 |
| Profit Margin | -39.3 % |
| Operating Margin | -2.1 % |
| Return on Assets (ttm) | 0.3 % |
| Return on Equity (ttm) | -46 % |
| Qtrly Rev. Growth | 2.7 % |
| Gross Profit (p.s.) | 17.49 |
| Sales Per Share | 38.93 |
| EBITDA (p.s.) | 7.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -57 (M) |
| Levered Free Cash Flow | 147 (M) |
| PE Ratio | -0.85 |
| PEG Ratio | 2 |
| Price to Book value | 0.5 |
| Price to Sales | 0.33 |
| Price to Cash Flow | -15.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|